Openbookopenbook
Equity
News Competition Stock Screener Home Portfolio Learn
Login
Diaceutics PLC(DXRX)
GBX --+0.00%
Reward57Moderate
Risk54Moderate
📊75%Data
Thin -4% profit margin · Revenue growing 18% YoY
DXRX
+0.0 · +0.00%
GBX · LSE
Diaceutics PLC | Healthcare
Profitless Growth
Market Cap:122.29M
ℹ️
Reward Rating
57
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
54
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on DXRX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 221p.

What is Diaceutics PLC?

Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies.

DXRX · Verdict

Solid reward · elevated risk

DXRX's standout is growth; cash flow and profitability weigh on the picture.

Based on 88% data coverage

DXRX · Verdict

What’s working & what to watch

Strengths 1

  • Growth82/100

    Revenue +32.1% CAGR

Watchouts 3

  • Cash flow27/100

    -12% free-cash-flow margin

  • Profitability32/100

    -5% net margin · -4% ROE

  • Valuation35/100

    P/E 172.4×

Model-based scoring. For information only — not financial advice.

What is Diaceutics PLC?

Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 122.29M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (57)

The scoring profile indicates moderate reward potential, with growth and momentum as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap122.29M
P/E RatioN/A
Dividend YieldN/A
52 Week High176.25
52 Week Low106
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares Outstanding85M
No. of Employees213
IndustryHealth Information Services
ExchangeLSE
Beta1.043
CurrencyGBX
Websitewww.diaceutics.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.